We are live on
!
Find out more
FFM
Fairmount Funds Management Portfolio holdings
AUM
$1.38B
1-Year Est. Return
407.79%
This Fund
S&P 500
This Quarter
Est. Return
+22.29%
1 Year Est. Return
+407.79%
3 Year Est. Return
+2,937.62%
5 Year Est. Return
+5,415.3%
10 Year Est. Return
–
AUM
$1.01B
AUM Growth
-$227M
(-18%)
Cap. Flow
-$15.2M
Cap. Flow
% of AUM
-1.51%
Top 10 Holdings %
Top 10 Hldgs %
80.48%
Holding
18
New
3
Increased
1
Reduced
3
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$63.9M |
| 2 |
AnaptysBio
ANAB
|
+$44M |
| 3 |
Inhibikase Therapeutics
IKT
|
+$15.3M |
| 4 |
ORKA
Oruka Therapeutics
ORKA
|
+$3.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$81.9M |
| 2 |
NUVL
Nuvalent
NUVL
|
+$34.5M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
+$23.1M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
+$2.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Axsome Therapeutics
AXSM
$12.3B
| $124M | 12.36% |
1,468,983
-891,094
| -38% | -$81.9M |
|
|
NUVL
2
DELISTED
Nuvalent
NUVL
| $103M | 10.25% |
1,317,664
-369,400
| -22% | -$34.5M |
|
3
Spyre Therapeutics
SYRE
$8.7B
| $93.5M | 9.3% |
4,018,101
| – | – |
|
4
Apogee Therapeutics
APGE
$10.2B
| $92.8M | 9.23% |
2,048,647
| – | – |
|
|
5
Scholar Rock
SRRK
$5.98B
| $84.8M | 8.43% |
+1,962,953
| New | +$63.9M |
|
6
Enliven Therapeutics
ELVN
$3.8B
| $72.1M | 7.16% |
3,202,798
| – | – |
|
7
Viridian Therapeutics
VRDN
$2.2B
| $66.1M | 6.57% |
3,445,813
| – | – |
|
|
ORKA
8
Oruka Therapeutics
ORKA
$5.51B
| $65.4M | 6.5% |
3,371,922
+160,000
| +5% | +$3.9M |
|
9
Dianthus Therapeutics
DNTH
$5.78B
| $58.9M | 5.85% |
2,700,691
| – | – |
|
10
Cogent Biosciences
COGT
$6.91B
| $48.6M | 4.83% |
6,225,641
| – | – |
|
|
11
Kiniksa Pharmaceuticals
KNSA
$4.97B
| $43.4M | 4.32% |
2,194,341
-1,010,500
| -32% | -$23.1M |
|
|
DAWN
12
DELISTED
Day One Biopharmaceuticals
DAWN
| $39.3M | 3.91% |
3,103,448
| – | – |
|
|
ATXS
13
DELISTED
Astria Therapeutics
ATXS
| $31.8M | 3.16% |
3,554,129
| – | – |
|
|
14
AnaptysBio
ANAB
$1.61B
| $24.1M | 2.39% |
+1,816,466
| New | +$44M |
|
|
BCAX
15
Bicara Therapeutics
BCAX
$1.86B
| $22.4M | 2.22% |
1,284,169
| – | – |
|
|
16
Inhibikase Therapeutics
IKT
$367M
| $19.9M | 1.98% |
+6,125,000
| New | +$15.3M |
|
|
ZBIO
17
Zenas BioPharma
ZBIO
$2.06B
| $15.5M | 1.54% |
1,892,806
| – | – |
|
|
BCYC
18
Bicycle Therapeutics
BCYC
$278M
| – | – |
-123,538
| Closed | -$2.8M |
|
Similar funds
NIP
OCAM
AU
RIM
VC
AO
1CP
OCM
Fairmount Funds Management's Q4 2024 Portfolio in Review
As of Q4 2024, Fairmount Funds Management held 18 positions worth $1.01B, down 18% from $1.23B the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Fairmount Funds Management's Q4 2024 filing shows 3 new, 1 increased, 3 reduced and 1 closed positions. Its largest new stake was Scholar Rock: 1,962,953 shares worth $84.8M. The largest sale was Axsome Therapeutics, an estimated $81.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Fairmount Funds Management's largest Q4 2024 buy was Scholar Rock: 1,962,953 shares worth $84.8M.
- Fairmount Funds Management added most to Oruka Therapeutics in Q4 2024, an estimated $3.9M increase.
- Fairmount Funds Management's biggest Q4 2024 reduction was Axsome Therapeutics, cutting an estimated $81.9M.
- Fairmount Funds Management fully exited Bicycle Therapeutics in Q4 2024, selling an estimated $2.8M.
- Fairmount Funds Management's ten largest holdings make up 80% of its $1.01B portfolio in Q4 2024.
- Fairmount Funds Management opened 3 new positions and closed 1 in Q4 2024.
- Fairmount Funds Management's portfolio value fell 18% quarter-over-quarter to $1.01B.
Based on Fairmount Funds Management's 13F filing for Q4 2024, filed 14 Feb 2025.